The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Psychiatric Side Effects of Interferon Therapy: Prevalence, Proposed Mechanisms, and Future Directions
Abstract
The increasing use of interferon (IFN) in treating a variety of disorders including, malignant melanoma and hepatitis C, has resulted in the identification and increasing concern about the psychiatric side effects that can result from treatment. These effects can occur either shortly after beginning IFN therapy or later as a result of continued treatment. Studies have reported the incidence of later side effects, which include symptoms of depression, anxiety, and occasional suicidal ideation, to be from 0% to 70%. Case studies have demonstrated that pharmacologic interventions are beneficial in reducing iatrogenic psychiatric symptoms while allowing patients to maintain IFN therapy. The present article provides an overview of the psychiatric effects of IFN therapy, the proposed mechanisms of these side effects, and case studies that provide mechanistic support. In addition, limitations of the current literature are provided with suggestions for treating physicians and a discussion of possible future research directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The brief symptom inventory: an introductory report.
Derogatis, L. R., & Melisaratos, N. (1983) · Psychological Medicine · doi:10.1017/s0033291700048017 · Cited by 6,650
"Serotonin Depression"—A Biochemical Subgroup Within the Affective Disorders?
Åsberg, M., Thorén, P., Traskman, L., Bertilsson, L., & Ringberger, V. (1976) · Science · doi:10.1126/science.1246632 · Cited by 682
Psychiatric Complications of Long-term Interferon Alfa Therapy
Renault, P. F. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090055011 · Cited by 413
Suicide associated with alfa-interferon therapy for chronic viral hepatitis
Janssen, H. L. A., Brouwer, J. T., van der Mast, R. C., & Schalm, S. W. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80402-7 · Cited by 229
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995) · Neurology · doi:10.1212/wnl.45.5.947 · Cited by 160
Cited by
Candidate mechanisms for chemotherapy-induced cognitive changes
Ahles, T. A., & Saykin, A. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2073 · Cited by 916
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
Side effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1002/hep.1840360730 · Cited by 556
Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. J., Meyers, C. A., Miller, A. H., Payne, R., Reuben, J. M., Wang, X. S., et al. (2003) · Cancer · doi:10.1002/cncr.11382 · Cited by 526
Anxiety Disorders in Cancer Patients: Their Nature, Associations, and Relation to Quality of Life
Stark, D., Kiely, M., Smith, A., Velikova, G., House, A., & Selby, P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.549 · Cited by 496
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Stark, D. P. H., & House, A. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1405 · Cited by 431
Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001119 · Cited by 313
ANDERSON-HANLEY, C., SHERMAN, M. L., RIGGS, R., AGOCHA, V. B., & COMPAS, B. E. (2003) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617703970019 · Cited by 302
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy: Prevalence and Prediction
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 299
Prevalence of anxiety among breast cancer patients: a systematic review and meta-analysis
Hashemi, S.-M., Rafiemanesh, H., Aghamohammadi, T., Badakhsh, M., Amirshahi, M., Sari, M., Behnamfar, N., & Roudini, K. (2020) · Breast Cancer · doi:10.1007/s12282-019-01031-9 · Cited by 243
Anterior Cingulate Activation and Error Processing During Interferon-Alpha Treatment
Capuron, L., Pagnoni, G., Demetrashvili, M., Woolwine, B. J., Nemeroff, C. B., Berns, G. S., & Miller, A. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.033 · Cited by 222
“Interferon-alpha is a potent activator of the inflammatory cytokine network and is well known to cause neuropsychiatric symptoms, including alterations in mood (depression, anxiety, tension/irritability), cognition, and neurovegetative function (Capuron et al 2002; Trask et al 2000).”
BackgroundInflammatory cytokine-associated depression
Lotrich, F. E. (2015) · Brain Research · doi:10.1016/j.brainres.2014.06.032 · Cited by 183
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100
“However, exogenous interferon-α2 (IFN-α) can potentially trigger major depression (MDD) in a subset of patients [2-4] similar to idiopathic MDD [5-8].”
BackgroundPsychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86
Lieb, K., Engelbrecht, M. A., Gut, O., Fiebich, B. L., Bauer, J., Janssen, G., & Schaefer, M. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.030 · Cited by 77
Franzen, P. L., Buysse, D. J., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.02.011 · Cited by 62
Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C
Amodio, P., De Toni, E. N., Cavalletto, L., Mapelli, D., Bernardinello, E., Del Piccolo, F., Bergamelli, C., Costanzo, R., Bergamaschi, F., Poma, S. Z., et al. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.09.004 · Cited by 61
Hepatitis C Treatment for People With Severe Mental Illness
Mistler, L. A., Brunette, M. F., Marsh, B. J., Vidaver, R. M., Luckoor, R., & Rosenberg, S. D. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.2.93 · Cited by 39
Rosgen, B. K., Moss, S. J., Fiest, K. M., McKillop, S., Diaz, R. L., Barr, R. D., Patten, S. B., Deleemans, J., & Fidler-Benaoudia, M. M. (2022) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkac077 · Cited by 27
Metadata
- Authors
- Trask, P. C., Esper, P., Riba, M., & Redman, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-06-11
- Volume
- 18
- Issue
- 11
- Pages
- 2316-2326
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1854131685
- Cited by
- 191
- References
- 5
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.